Tirzepatide, a weekly GLP-1 and GIP drug, produced weight loss of up to 17.8% after 72 weeks. Semaglutide, a weekly GLP-1 drug, caused weight loss of up to 13.9% after 68 weeks. Liraglutide, a daily GLP-1 drug, brought weight loss of up to 5.8% after 26 weeks.

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would drugmakers agree to reduce their prices right away?

GLP-1 drugs such as Ozempic and Wegovy are driving down grocery spending, according to a new study from Cornell’s SC Johnson College of Business and consumer data firm Numerator.

A study in pigs has shown that the active ingredient in Ozempic and Wegovy directly boosts heart health, in addition to the benefits of losing weight

Indiana’s Medicaid program estimates the Biden administration’s proposal to expand coverage of weight-loss treatment for people with obesity could cost it up to $70 million a year, covering up to 20% of eligible enrollees.

Weight loss tops many folks’ list of New Years resolutions, and lots of people are turning to cutting-edge weight-loss drugs like Ozempic to help them drop excess pounds. These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs),

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

GLP-1 drugs spiked in popularity and price over the past few years, leaving the door open for illegal pharmacies to try and sell cheaper counterfeit versions.